Published

13 Dec 25

Updated

16 Aug 26

Views

46

Not Invested

Alpha CognitionACOG

Fair Value

US$16.75

Share price16 Aug

US$9.1645.3% undervalued

Loading

1Y10.36%

7D-6.05%

Long-Term Care Adoption And International Expansion Will Drive Durable Cognitive Therapy Demand

AN

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

13 Dec 25

Updated

16 Aug 26

Views

46

Not Invested

Shared on 16 Aug 26

Fair value Increased 14%

ACOG: Phase 4 Tolerability And Payer Progress Will Support Future Launch

A new study starts tracking how well people stick with Zunveyl in everyday care, a key test of whether it can avoid the stomach side effects that make many existing Alzheimer’s drugs hard to stay on. Investors are also watching whether broader insurance coverage and a newly granted European patent help the launch gain traction.

3 views

Shared on 10 Jul 26

Fair value Decreased 27%

ACOG: Phase 4 Tolerability Study Will Drive Future Alzheimer’s Launch Traction

A new real‑world study starts tracking how well people stay on Zunveyl and how they handle side effects in everyday care, which could help doctors feel more comfortable prescribing it. Analysts still see a big market, but they dial back expectations because the launch is early and the drug’s staying power with patients and insurers is still uncertain.

3 views

Fair Value vs Share Price

US$16.75

vs US$9.1645.3% undervalued

144.3%

Revenue growth

15.8%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Alpha Cognition

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

High growth potential with excellent balance sheet.

Market capUS$199.5m

PB3.8x

Estimated Growth43.2%

Dividend YieldN/A

CEO & management

Michael McFadden

CEO

4.1yrs

CEO Tenure

A biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.